Wan Rosmawati Wan Ismail and Mohd Shafik Abd Majid and Hua Yeh Li and Mohd Faizal Madrim and Syed Sharizman Syed Abdul Rahim and Mohammad Saffree Jeffree and Zahir Izuan Azhar and Hasanain Faisal Ghazi and Mohd Rohaizat Hassan (2020) Safety of dengue vaccine (CYD-TDV) in Asia: A systematic review. Russian Journal of Infection and Immunity Infektsiya i immunitet. ISSN 2220-7619
|
Text
Safety of dengue vaccine (CYD-TDV) in Asia.pdf Download (49kB) | Preview |
Abstract
Application Dengue fever vaccine (CYD-TDV) in Asia currently remains quite limited and controversial due to safety issues not yet adequately evaluated. Therefore, the purpose of our review was to assess the safety of the CYD-TDV vaccine based on an analysis of data on its effectiveness in Asia. A search for relevant keywords in electronic databases found 309 scientific articles, of which only four publications were included in the review. The baseline serotype prevalence among study participants was 50-80%. With regard to the safety of the CYD-TDV vaccine, it was shown that reactions at the injection site (pain, edema, erythema) were noted with a relative risk (RR) of 95% CI (0.46-1.76), and systemic reactions (fever, headache, myalgia) were also RR 95% CI (0.89-1.81). Of the four papers included in the review, three contain data on a number of severe adverse effects at RR 95% CI (0.92-2.11). With regard to immunity, it was shown that for DENV-2 there was a high geometric mean titer of 67.8 (95% CI 64.8-70.8), DENV-3 - in 73.1 (95% CI 69.9-76.3), and for DENV-4 - in 65 ( 95% CI 62-67.9), when even lower values are found, this is consistent with other published work on the immunogenicity of the CYD-TDV vaccine against DENV serotypes. Our review shows that the CYD-TDV vaccine may be considered for use in Asia, but subject to a number of conditions and following these safety guidelines. 3), and for DENV-4 - in 65 (95% CI 62-67.9), when, when even smaller values are found, this is consistent with other published works on the immunogenicity of the CYD-TDV vaccine against DENV serotypes. Our review shows that the CYD-TDV vaccine may be considered for use in Asia, but subject to a number of conditions and following these safety guidelines. 3), and for DENV-4 - in 65 (95% CI 62-67.9), when, when even smaller values are found, this is consistent with other published works on the immunogenicity of the CYD-TDV vaccine against DENV serotypes. Our review shows that the CYD-TDV vaccine may be considered for use in Asia, but subject to a number of conditions and following these safety guidelines.
| Item Type: | Article |
|---|---|
| Keyword: | Dengue vaccine, CYD-TDV, safety, adult, children, Asia |
| Subjects: | R Medicine > R Medicine (General) R Medicine > RA Public aspects of medicine |
| Department: | FACULTY > Faculty of Medicine and Health Sciences |
| Depositing User: | SITI AZIZAH BINTI IDRIS - |
| Date Deposited: | 15 Oct 2020 07:33 |
| Last Modified: | 15 Oct 2020 07:33 |
| URI: | https://eprints.ums.edu.my/id/eprint/26083 |
Actions (login required)
 |
View Item |